• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在口服治疗之前,我们对埃及的丙型肝炎病毒4型(HCV-4)了解多少:一项利用数据挖掘计算分析对患病率和风险进行的随机调查。

Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis.

作者信息

Abd Elrazek Abd Elrazek, Bilasy Shymaa E, Elbanna Abduh E M, Elsherif Abd Elhalim A

机构信息

From the Department of Tropical Medicine, GIT & Hepatology, Faculty of Medicine, Al Azhar University, Al Azhar University Hospitals; Asiut & Cairo (AEMAAE, AEAEs); Department of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia (SEB); and Department of General, Laparoscopic and Bariatric Surgery, Al Husain University Hospital, Faculty of Medicine, Al Azhar University, Cairo, Egypt (AEb).

出版信息

Medicine (Baltimore). 2014 Dec;93(28):e204. doi: 10.1097/MD.0000000000000204.

DOI:10.1097/MD.0000000000000204
PMID:25526438
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4603091/
Abstract

Hepatitis C virus (HCV) affects over 180 million people worldwide and it's the leading cause of chronic liver diseases and hepatocellular carcinoma. HCV is classified into seven major genotypes and a series of subtypes. In general, HCV genotype 4 (HCV-4) is common in the Middle East and Africa, where it is responsible for more than 80% of HCV infections. Although HCV-4 is the cause of approximately 20% of the 180 million cases of chronic hepatitis C worldwide, it has not been a major subject of research yet. The aim of the current study is to survey the morbidities and disease complications among Egyptian population infected with HCV-4 using data mining advanced computing methods mainly and other complementary statistical analysis. Six thousand six hundred sixty subjects, aged between 17 and 58 years old, from different Egyptian Governorates were screened for HCV infection by ELISA and qualitative PCR. HCV-positive patients were further investigated for the incidence of liver cirrhosis and esophageal varices. Obtained data were analyzed by data mining approach. Among 6660 subjects enrolled in this survey, 1018 patients (15.28%) were HCV-positive. Proportion of infected-males was significantly higher than females; 61.6% versus 38.4% (P=0.0052). Around two-third of infected-patients (635/1018; 62.4%) were presented with liver cirrhosis. Additionally, approximately half of the cirrhotic patients (301/635; 47.4%) showed degrees of large esophageal varices (LEVs), with higher variceal grade observed in males. Age for esophageal variceal development was 47±1. Data mining analysis yielded esophageal wall thickness (>6.5 mm), determined by conventional U/S, as the only independent predictor for esophageal varices. This study emphasizes the high prevalence of HCV infection among Egyptian population, in particular among males. Egyptians with HCV-4 infection are at a higher risk to develop cirrhotic liver and esophageal varices. Data mining, a new analytic technique in medical field, shed light in this study on the clinical importance of esophageal wall thickness as a useful predictor for risky esophageal varices using decision tree algorithm.

摘要

丙型肝炎病毒(HCV)在全球感染超过1.8亿人,是慢性肝病和肝细胞癌的主要病因。HCV分为七个主要基因型和一系列亚型。一般来说,HCV基因型4(HCV-4)在中东和非洲较为常见,在这些地区,它导致了超过80%的HCV感染。尽管HCV-4在全球1.8亿例慢性丙型肝炎病例中约占20%,但它尚未成为主要的研究对象。本研究的目的主要是使用数据挖掘先进计算方法以及其他补充性统计分析,调查感染HCV-4的埃及人群中的发病率和疾病并发症。对来自埃及不同省份的6660名年龄在17至58岁之间的受试者进行了ELISA和定性PCR检测,以筛查HCV感染。对HCV阳性患者进一步调查肝硬化和食管静脉曲张的发病率。所获数据采用数据挖掘方法进行分析。在参与本次调查的6660名受试者中,1018名患者(15.28%)HCV呈阳性。感染男性的比例显著高于女性;分别为61.6%和38.4%(P = 0.0052)。约三分之二的感染患者(635/1018;62.4%)患有肝硬化。此外,大约一半的肝硬化患者(301/635;47.4%)出现不同程度的大食管静脉曲张(LEV),男性的静脉曲张分级更高。食管静脉曲张发生的年龄为47±1岁。数据挖掘分析得出,通过传统超声测定的食管壁厚度(>6.5毫米)是食管静脉曲张的唯一独立预测指标。本研究强调了HCV感染在埃及人群中,尤其是男性中的高患病率。感染HCV-4的埃及人发生肝硬化和食管静脉曲张的风险更高。数据挖掘作为医学领域的一种新分析技术,在本研究中利用决策树算法揭示了食管壁厚度作为危险食管静脉曲张有用预测指标的临床重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d0/4603091/558834ac76b6/medi-93-e204-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d0/4603091/6e27590b23d5/medi-93-e204-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d0/4603091/999e7c5c9b76/medi-93-e204-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d0/4603091/558834ac76b6/medi-93-e204-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d0/4603091/6e27590b23d5/medi-93-e204-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d0/4603091/999e7c5c9b76/medi-93-e204-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d0/4603091/558834ac76b6/medi-93-e204-g009.jpg

相似文献

1
Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis.在口服治疗之前,我们对埃及的丙型肝炎病毒4型(HCV-4)了解多少:一项利用数据挖掘计算分析对患病率和风险进行的随机调查。
Medicine (Baltimore). 2014 Dec;93(28):e204. doi: 10.1097/MD.0000000000000204.
2
Incidence of HCV induced-Esophageal varices in Egypt: Valuable knowledge using data mining analysis.埃及丙型肝炎病毒诱发食管静脉曲张的发病率:运用数据挖掘分析得出的宝贵知识
Medicine (Baltimore). 2017 Jan;96(4):e5647. doi: 10.1097/MD.0000000000005647.
3
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.奥比他韦、帕利瑞韦、利托那韦和利巴韦林联合治疗埃及丙型肝炎病毒基因型 4 感染合并或不合并代偿性肝硬化患者(AGATE-II):一项多中心、3 期、部分随机、开放标签试验。
Lancet Gastroenterol Hepatol. 2016 Sep;1(1):36-44. doi: 10.1016/S2468-1253(16)30002-4. Epub 2016 Jun 16.
4
Effect of schistosomiasis and hepatitis on liver disease.血吸虫病和肝炎对肝脏疾病的影响。
Am J Trop Med Hyg. 1999 Jun;60(6):915-20. doi: 10.4269/ajtmh.1999.60.915.
5
Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni.临床、病毒学及组织病理学特征:慢性丙型肝炎合并曼氏血吸虫感染患者的长期随访
Liver. 2000 Jul;20(4):281-9. doi: 10.1034/j.1600-0676.2000.020004281.x.
6
Real life application of FIB-4 & APRI during mass treatment of HCV genotype 4 with directly acting anti-viral agents in Egyptian patients, an observational study.埃及患者接受直接作用抗病毒药物治疗 HCV 基因型 4 时 FIB-4 和 APRI 的实际应用:一项观察性研究。
Expert Rev Gastroenterol Hepatol. 2019 Dec;13(12):1189-1195. doi: 10.1080/17474124.2019.1690990. Epub 2019 Nov 20.
7
An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.埃及消除丙型肝炎感染的教育、检测与治疗模式:73个村庄的可行性与有效性
J Hepatol. 2020 Apr;72(4):658-669. doi: 10.1016/j.jhep.2019.11.004. Epub 2019 Nov 14.
8
Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.索磷布韦联合利巴韦林治疗肝硬化合并基因 2 型 HCV 感染患者:真实世界经验。
J Hepatol. 2017 Apr;66(4):711-717. doi: 10.1016/j.jhep.2016.12.002. Epub 2016 Dec 10.
9
Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter?希腊和埃及丙型肝炎基因型 4 患者持续病毒学应答的预测因素:种族重要吗?
J Med Virol. 2012 Aug;84(8):1217-23. doi: 10.1002/jmv.23324.
10
Sustained virological response: a milestone in the treatment of chronic hepatitis C.持续病毒学应答:慢性丙型肝炎治疗的里程碑。
World J Gastroenterol. 2013 May 14;19(18):2793-8. doi: 10.3748/wjg.v19.i18.2793.

引用本文的文献

1
Geographic diversity of human liver cancers mirrors global social inequalities.人类肝癌的地理多样性反映了全球社会不平等现象。
Front Oncol. 2025 May 16;15:1565692. doi: 10.3389/fonc.2025.1565692. eCollection 2025.
2
Circulating miRNA-192 and miR-29a as Disease Progression Biomarkers in Hepatitis C Patients with a Prevalence of HCV Genotype 3.循环 miRNA-192 和 miR-29a 作为丙型肝炎患者 HCV 基因 3 型流行中的疾病进展生物标志物。
Genes (Basel). 2023 May 8;14(5):1056. doi: 10.3390/genes14051056.
3
Gender differences in prevalence of hepatitis C virus infection in Egypt: a systematic review and meta-analysis.

本文引用的文献

1
Screening esophagus during routine ultrasound: medical and cost benefits.在常规超声检查时筛查食管:医学及成本效益
Eur J Gastroenterol Hepatol. 2015 Jan;27(1):8-12. doi: 10.1097/MEG.0000000000000196.
2
Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.丙型肝炎病毒异质性对干扰素敏感性的影响:综述
World J Gastroenterol. 2014 Jun 28;20(24):7555-69. doi: 10.3748/wjg.v20.i24.7555.
3
Association of genetic variants in estrogen receptor α with HCV infection susceptibility and viral clearance in a high-risk Chinese population.
埃及丙型肝炎病毒感染患病率的性别差异:系统评价和荟萃分析。
Sci Rep. 2023 Feb 13;13(1):2499. doi: 10.1038/s41598-023-29262-z.
4
Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt.埃及一个主要省份大学生中丙型肝炎病毒感染率呈下降趋势。
Infect Drug Resist. 2018 Nov 22;11:2435-2441. doi: 10.2147/IDR.S183462. eCollection 2018.
5
Treatment of hepatitis C virus genotype 4 in the DAA era.DAA 时代丙型肝炎病毒基因型 4 的治疗。
Virol J. 2018 Nov 22;15(1):180. doi: 10.1186/s12985-018-1094-4.
6
Hepatitis C virus infection in children in the era of direct-acting antiviral.直接作用抗病毒药物时代儿童丙型肝炎病毒感染
World J Gastroenterol. 2018 Jun 28;24(24):2555-2566. doi: 10.3748/wjg.v24.i24.2555.
7
Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village.索磷布韦联合达卡他韦治疗埃及患者队列中的慢性丙型肝炎4型感染:一项埃及村庄规模的实验。
Int J Hepatol. 2018 Mar 20;2018:9616234. doi: 10.1155/2018/9616234. eCollection 2018.
8
Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection.索磷布韦-来迪帕司韦治疗一组埃及慢性丙型肝炎基因4型感染患者的疗效和安全性。
Infect Drug Resist. 2018 Mar 1;11:295-298. doi: 10.2147/IDR.S153060. eCollection 2018.
9
Liver stiffness measurement and spleen diameter as predictors for the presence of esophageal varices in chronic hepatitis C patients.肝脏硬度测量和脾脏直径作为慢性丙型肝炎患者食管静脉曲张存在的预测指标。
Medicine (Baltimore). 2017 Nov;96(46):e8621. doi: 10.1097/MD.0000000000008621.
10
Ongoing Transmission of HCV: Should Cesarean Section be Justified? Data Mining Discovery.丙型肝炎病毒的持续传播:剖宫产是否合理?数据挖掘发现
J Transl Int Med. 2017 Mar 31;5(1):27-33. doi: 10.1515/jtim-2017-0001. eCollection 2017 Mar.
雌激素受体α基因变异与高危中国人群丙型肝炎病毒感染易感性及病毒清除的关联
Eur J Clin Microbiol Infect Dis. 2014 Jun;33(6):999-1010. doi: 10.1007/s10096-013-2038-y. Epub 2014 Jan 7.
4
Sofosbuvir for the treatment of hepatitis C virus.索非布韦治疗丙型肝炎病毒。
Expert Opin Pharmacother. 2014 Jan;15(1):121-30. doi: 10.1517/14656566.2014.857656. Epub 2013 Nov 30.
5
Mortality prediction of nonalcoholic patients presenting with upper gastrointestinal bleeding using data mining.使用数据挖掘预测非酒精性上消化道出血患者的死亡率。
Eur J Gastroenterol Hepatol. 2014 Feb;26(2):187-91. doi: 10.1097/MEG.0b013e328365c3b0.
6
Hepatitis C virus genotypes in north eastern Algeria: A retrospective study.阿尔及利亚东北部的丙型肝炎病毒基因型:一项回顾性研究。
World J Hepatol. 2013 Jul 27;5(7):393-7. doi: 10.4254/wjh.v5.i7.393.
7
Epidemiology and natural history of HCV infection.丙型肝炎病毒感染的流行病学和自然史。
Nat Rev Gastroenterol Hepatol. 2013 Sep;10(9):553-62. doi: 10.1038/nrgastro.2013.107. Epub 2013 Jul 2.
8
The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis.埃及丙型肝炎病毒的流行病学:系统评价和数据综合。
BMC Infect Dis. 2013 Jun 24;13:288. doi: 10.1186/1471-2334-13-288.
9
Coinfection with hepatitis C virus and schistosomiasis: fibrosis and treatment response.丙型肝炎病毒和血吸虫病合并感染:纤维化和治疗反应。
World J Gastroenterol. 2013 May 7;19(17):2691-6. doi: 10.3748/wjg.v19.i17.2691.
10
From data towards knowledge: revealing the architecture of signaling systems by unifying knowledge mining and data mining of systematic perturbation data.从数据到知识:通过统一系统扰动数据的知识挖掘和数据挖掘来揭示信号系统的结构。
PLoS One. 2013 Apr 23;8(4):e61134. doi: 10.1371/journal.pone.0061134. Print 2013.